Heme oxygenase-1 inducer hemin prevents vascular thrombosis

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 614-620

  Desbuards, Nicolas ^a   Rochefort, Gaël Y ^a   Schlecht, Deborah ^a   Machet, Marie Christine ^a   Halimi, Jean Michel ^a   Eder, Véronique ^a   Hyvelin, Jean Marc ^a   Antier, Daniel ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Hemin; Rat; Vascular thrombosis

Indexed keywords

HEME OXYGENASE 1; HEMIN; MESSENGER RNA; PROTOPORPHYRIN TIN; RECOMBINANT THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY; CONTROLLED STUDY; ELECTROSTIMULATION; HEMOSTASIS; HISTOPATHOLOGY; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; THROMBOSIS; TREATMENT DURATION;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ENZYME INDUCTION; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; HEME; HEME OXYGENASE (DECYCLIZING); HEMIN; LEUKOCYTE COUNT; MALE; METALLOPORPHYRINS; PLATELET COUNT; PROTOPORPHYRINS; RATS; RATS, WISTAR; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 34548687462     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-12-0717     Document Type: Article

References (42)

1. Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation 2004; 110(24 Suppl 1): IV13-19.
2. Feres F, Costa JR, Jr., Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 2006; 68: 83-88.
3. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
4. Andtbacka RH, Babiera G, Singletary SE, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006; 243: 96-101.
5. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 287S-310S.
6. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
7. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1: 1602-1612.
8. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
9. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905.
10. Kikuchi G, Yoshida T, Noguchi M. Heme oxygenase and heme degradation. Biochem Biophys Res Commun 2005; 338: 558-567.
11. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-554.
12. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 1786-1795.
13. Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6: 422-428.
14. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003; 55: 551-571.
15. Wunder C, Potter RF. The heme oxygenase system: its role in liver inflammation. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3: 199-208.
16. Duckers HJ, Boehm M, True AL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001; 7: 693-698.
17. Morita T, Mitsialis SA, Koike H, et al. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem 1997; 272: 32804-32809.
18. Peyton KJ, Reyna SV, Chapman GB, et al. Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood 2002; 99: 4443-4448.
19. Tulis DA, Keswani AN, Peyton KJ, et al. Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. Cell Mol Biol (Noisy-le-grand) 2005; 51: 441-446.
20. Brouard S, Otterbein LE, Anrather J, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000; 192: 1015-1026.
21. Brouard S, Berberat PO, Tobiasch E, et al. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J Biol Chem 2002; 277: 17950-17961.
22. Silva G, Cunha A, Gregoire IP, et al. The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38 alpha MAPK isoform. J Immunol 2006; 177: 1894-1903.
23. Mansouri A, Perry CA. Alteration of platelet aggregation by cigarette smoke and carbon monoxide. Thromb Haemost 1992; 48: 286-298.
24. Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32: 497-504.
25. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
26. Kawasaki T, Sato K, Hirayama F, et al. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis. Thromb Haemost 1998; 79: 859-864.
27. Braggins PE, Trakshel GM, Kutty RK, et al. Characterization of two heme oxygenase isoforms in rat spleen: comparison with the hematin-induced and constitutive isoforms of the liver. Biochem Biophys Res Commun 1986; 141: 528-533.
28. Shamloul R, Wang R. Monitoring circulatory heme level in hemin therapy for lowering blood pressure in rats. Cell Mol Biol (Noisy-le-grand) 2005; 51: 507-512.
29. Rochefort GY, Libgot R, Dcsbuards N, et al. Effect of the heme oxygenase inducer hemin on blood haemostasis measured by high-frequency ultrasound. Clin Exp Pharmacol P. 2007; in press.
30. Ishikawa K, Sugawara D, Wang X, et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 2001; 88: 506-512.
31. Lindenblatt N, Bordel R, Schareck W, et al. Vascular heme oxygenase-1 induction suppresses microvascular thrombus formation in vivo. Arterioscler Thromb Vasc Biol 2004; 24: 601-606.
32. Song R, Mahidhara RS, Zhou Z, et al. Carbon monoxide inhibits T lymphocyte proliferation via caspase-dependent pathway. J Immunol 2004; 172: 1220-1226.
33. Pae HO, Oh GS, Choi BM, et al. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J Immunol 2004; 172: 4744-4751.
34. Suzuki S, Kassell NF, Lee KS. Hemin activation of an inducible isoform of nitric oxide synthase in vascular smooth-muscle cells. J Neurosurg 1995; 83: 862-866.
35. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-1775.
36. Jacob SW, Herschler R. Pharmacology of DMSO. Cryobiology 1986; 23: 14-27.
37. Saeed SA, Karimi SJ, Suria A. Differential effects of dimethyl sulfoxide on human platelet aggregation and arachidonic acid metabolism. Biochem Med Metab Biol 1988; 40: 143-150.
38. Gorog P, Kovacs IB. Antiarthritic and antithrombotic effects of topically applied dimethyl sulfoxide. Ann NY Acad Sci 1975; 243: 91-97.
39. Peng L, Mundada L, Stomel JM, et al. Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal 2004; 6: 729-735.
40. Amer J, Fibach E. Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost 2004; 92: 1052-1059.
41. Glueck R, Green D, Cohen I, et al. Hematin: unique effects of hemostasis. Blood 1983; 61: 243-249.
42. Volin L, Rasi V, Vahtera E, et al. Heme arginate: effects on hemostasis. Blood 1988; 71: 625-628.